A continuing research programme
ATDS looks beyond ingredient quantity to examine release from the finished formulation layer-specific delivery and evidence at the intended skin or follicular site Each annual English edition is available to read online
Research scope
Intact skin and non-invasive scalp
Oral sublingual and other mucosal absorption remains outside the ATDS conformity scope and must not be called transdermal delivery
Industrialization and stability
Particle profile as a quality attribute plus lyophilization formulation stability batch consistency and shelf life
Consumer-grade evaluation
Evidence tiers including Franz diffusion cells reconstructed epidermis and safety testing
Scientific publishing by tiptop
ATDS shares the knowledge developed as tiptop explores the future of precision delivery with researchers developers and manufacturing partners worldwide
ExosomeBeta-
All tiptop raw-material programs are developed and evaluated within ATDS For EV raw materials ExosomeBeta- is tiptop's proprietary brand designation for material meeting the applicable tiptop ATDS specifications and evidence requirements It is not a scientific EV subtype or a regulatory classification
ATDS CONSUMER GUIDE
How ATDS helps interpret product evidence
ATDS looks at products through three interconnected evidence chains: Is the raw-material identity clear? Does the delivery conclusion come from the final formulation? Do the human results correspond to the same finished product? Read the consumer guide to learn how these three questions help determine whether the information for an exosome skincare product is complete.
2026 · ATDS White Paper
ATDS is researched developed and published by tiptop as an enterprise technical white paper for evidence-led delivery on intact skin and the non-invasive scalp